Biogen

Yahoo Finance • 3 days ago

Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Argus upgraded Ulta Beauty(ULTA) to Bu... Full story

Yahoo Finance • 4 days ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbach... Full story

Yahoo Finance • 4 days ago

Biogen gets complete response letter from FDA for higher dose Spinraza

[Neuron system disease] koto_feja/E+ via Getty Images Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) reported that the U.S. FDA has declined to accept its request for a supplemental marketing authorization for a higher dose o... Full story

Yahoo Finance • 4 days ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application... Full story

Yahoo Finance • 6 days ago

Analysts See 10% Gains Ahead For CATH

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 10 days ago

Biogen to buy Massachusetts-based Alcyone Therapeutics

[Neuron system disease] koto_feja/E+ via Getty Images Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) said that it has agreed to acquire Alcyone Therapeutics, a company based in Massachusetts. The deal involves an upfront pay... Full story

Yahoo Finance • 10 days ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs)ThecaFlex DRx™ has the potential to be a new, convenient way... Full story

Yahoo Finance • 10 days ago

Biogen gets EU nod for Zurzuvae to treat post-partum depression

[Neuron system disease] koto_feja/E+ via Getty Images * Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) said that the European Commission has granted approval for Zurzuvae (zuranolone) to treat post-partum depression. * Zu... Full story

Yahoo Finance • 10 days ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of thi... Full story

Yahoo Finance • 13 days ago

H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects

Biogen Inc. (NASDAQ:BIIB) is one of the best defensive stocks to buy, according to Steve Cohen. On September 5, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $194 price target. The positive stance echoes the research firm’s... Full story

Yahoo Finance • 13 days ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 18 days ago

8MM Alzheimer's Disease Market Drug Forecast and Market Analysis 2025-2033 | Eisai, Biogen, and Lilly to Lead, Novel Late-stage Pipeline Drugs Will Be a Key Driver, Opportunities in Unmet Needs

Company Logo Alzheimer’s market growth opportunities lie in developing disease-modifying treatments and anti-Aβ monoclonal antibodies, driven by unmet needs in AD therapies. The US and China dominate sales, with future expansions anticipa... Full story

Yahoo Finance • 18 days ago

White House mulls restrictions on medicines invented in China: NYT

[capsules showcases the flag of United State of America and China] Love Employee/iStock via Getty Images White House officials are working on a draft executive order, which, if enacted, could impose harsh restrictions on experimental trea... Full story

Yahoo Finance • 18 days ago

Three key points from the new MAHA report

[President Trump Attends MAHA Commission Event At White House] Chip Somodevilla/Getty Images News The Trump administration’s Make America Healthy Again Commission released its second report on Tuesday, noting that dietary factors, synthet... Full story

Yahoo Finance • 20 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Opendoor Technologies Inc. 136,631,575 7.32 6.86 6.875 +0.225 Eightco Ho... Full story

Yahoo Finance • 21 days ago

Notable healthcare headlines for the week: Novartis, Cigna and Sanofi in focus

Wall Street’s broader market averages finished Friday lower after taking back earlier gains on Friday. At the end of trading the blue-chip Dow(DJI [https://seekingalpha.com/symbol/DJI]) handed back 0.48% while the benchmark S&P 500 (SP500... Full story

Yahoo Finance • 24 days ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics, Inc. Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical c... Full story

Yahoo Finance • 24 days ago

Notable Wednesday Option Activity: WDC, ADBE, BIIB

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Western Digital Corp (Symbol: WDC), where a total volume of 31,773 contracts has been traded thus far today, a contract volume... Full story

Yahoo Finance • 25 days ago

Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) and Eisai (OTCPK:ESAIY [https://seekingalpha.com/symbol/ESAIY]) announced... Full story

Yahoo Finance • 25 days ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbach... Full story